OncoBeta GmbH® Announces Certification of its New Production Facility Partner MAP Medical Technologies Oy, Tikkakoski FINLAND

Garching n. Munich, Germany, (June 08, 2018) – OncoBeta GmbH has today announced the certification of its new production facility partner MAP Medical Technologies Oy, Tikkakoski FINLAND, aiming to deliver OncoBeta GmbH’s high-quality products to more patients in a timely manner as well as further address rising patients’ needs. MAP Medical Technologies is a GMP production facility specializing in radiopharmaceuticals which is equipped with OncoBeta’s cutting edge technology to produce our Rhenium-188 compound carpoules in the fight against Non-Melanoma Skin Cancer.
“The new production facility plays a key role in OncoBeta’s global manufacturing network.” Says Shannon D. Brown III, CEO and Managing Director of OncoBeta GmbH. “With this new production facility, we can efficiently service Europe, the entire African continent as well as Canada and Australia. We continuously invest in our technologies to ensure a stable supply of the highest-quality products to physicians and patients around the world. The expanded production capacity will make it possible to meet the increased demand in global markets.”

About the Rhenium-SCT® (Skin Cancer Therapy)

The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients’ skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

About OncoBeta® GmbH

OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the EU.

Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Download PDF Version